Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

437

Citations

22

References

2010

Year

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock, Scot Ebbinghaus, Peter J. O’Dwyer, Michael S. Gordon, William Novotny, Meredith A. Goldwasser, Tanyifor M. Tohnya, Bert L. Lum,

Journal of Clinical Oncology

Abstract

At the tested schedule and dose range, rhApo2L/TRAIL was safe and well tolerated. Dose escalation achieved peak rhApo2L/TRAIL serum concentrations equivalent to those associated with preclinical antitumor efficacy.

References

	Year	Citations

Page 1